GlassScriptPhysician profile
Suzanne Hewes
NPI 1528180171
$2,524.37
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $721 · 2023: $572 · 2024: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $292.26 | 2021-2024 | |
| Ucb, INC. | $202.66 | 2021-2024 | Briviact, Nayzilam |
| Lilly USA, LLC | $193.89 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Catalyst Pharmaceuticals, INC. | $178.37 | 2021-2024 | Fycompa |
| Lundbeck LLC | $162.78 | 2021-2024 | Vyepti |
| Abbvie INC. | $135.90 | 2022-2024 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Uplizna |
| Neuronetics, INC. | $122.10 | 2024 | Neurostar Tms Therapy System |
| Alexion Pharmaceuticals, INC. | $107.67 | 2021-2024 | Ultomiris |
| Neurelis, INC. | $106.39 | 2022-2024 | Valtoco |
| Biogen, INC. | $84.34 | 2022-2024 | Tysabri, Vumerity, Avonex |
| Pfizer INC. | $80.18 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.83 | 2021-2024 | Hyqvia |
| Merz Pharmaceuticals, LLC | $73.34 | 2021-2023 | Xeomin |
| Jazz Pharmaceuticals INC. | $66.39 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $65.54 | 2022-2024 | |
| Greenwich Biosciences, INC. | $48.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.09 | 2024 | |
| Amgen INC. | $38.08 | 2021-2022 | |
| Tanabe Pharma America, INC. | $37.00 | 2021-2023 | |
| Csl Behring | $35.28 | 2021-2022 | |
| Harmony Biosciences LLC | $31.66 | 2024 | |
| Argenx US, INC. | $29.10 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.28 | 2023 | Lifevest |
| Genzyme Corporation | $22.79 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $22.53 | 2023 | Relyvrio |
| Biohaven Pharmaceuticals, INC. | $21.62 | 2021 | |
| Medicomp INC | $21.31 | 2024 | Telepatch Cardiac Monitor |
| Avadel Cns Pharmaceuticals, LLC | $20.75 | 2024 | Lumryz |
| Sk Life Science, INC. | $20.23 | 2023 | |
| Neurocrine Biosciences, INC. | $16.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Hewes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.